A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
A DecensiUmberto Omodei

Abstract

Oral conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) increase breast cancer risk, whereas the effect of transdermal estradiol (E2) and MPA is less known. Fenretinide may decrease second breast malignancies in premenopausal women but not in postmenopausal women, suggesting a hormone-sensitizing effect. We compared the 6 and 12-month changes in insulin-like growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), IGF-I:IGFBP-3 ratio, sex-hormone binding-globulin, and computerized mammographic percent density during oral CEE or transdermal E2 with sequential MPA and fenretinide or placebo. A total of 226 recent postmenopausal healthy women were randomly assigned in a two-by-two factorial design to either oral CEE 0.625 mg/day (n = 111) or transdermal E2, 50 microg/day (n = 115) and to fenretinide 100 mg/twice a day (n = 112) or placebo (n = 114) for 12 months. Treatment effects were investigated by the Kruskall-Wallis test and analysis of covariance. P values were two-sided. After 12 months, oral CEE decreased IGF-I by 26% [95% confidence interval (CI), 22-30%] and increased sex-hormone binding-globulin by 96% (95% CI, 79-112%) relative to baseline, whereas no change occurred with transdermal E2 (P < 0.001 ...Continue Reading

References

Nov 15, 1995·Journal of the National Cancer Institute·R Lotan
Nov 1, 1995·Journal of the National Cancer Institute·C ByrneR Haile
Sep 1, 1995·American Journal of Obstetrics and Gynecology·L E Nachtigall
Nov 1, 1994·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·T C HillardJ C Stevenson
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F FormelliU Veronesi
Jun 19, 1997·The New England Journal of Medicine·F GrodsteinF E Speizer
Jun 17, 1998·International Journal of Cancer. Journal International Du Cancer·R TorrisiA Decensi
Nov 5, 1999·Journal of the National Cancer Institute·M H GailV Vogel
Nov 5, 1999·Journal of the National Cancer Institute·U VeronesiM B Sporn
Nov 10, 2000·International Journal of Cancer. Journal International Du Cancer·P TonioloA Zeleniuch-Jacquotte
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T CameriniU Veronesi
Jan 5, 2002·Breast Cancer Research and Treatment·B BonanniA Decensi
Jan 25, 2002·Annals of the New York Academy of Sciences·V Stern
Apr 12, 2002·Lancet·U VeronesiUNKNOWN Italian Tamoxifen Study Group
Apr 18, 2002·Journal of the National Cancer Institute·T KeyUNKNOWN Endogenous Hormones and Breast Cancer Collaborative Group
Jun 21, 2002·Cancer Causes & Control : CCC·Rudolf KaaksGöran Hallmans
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Oct 10, 2002·British Journal of Cancer·N F BoydS Minkin
Oct 22, 2002·The Journal of Biological Chemistry·Anat Erdreich-EpsteinMelissa Millard
Jan 2, 2003·Journal of the National Cancer Institute·Rowan T Chlebowski, Anne McTiernan
Jan 2, 2003·Journal of the National Cancer Institute·Gail A GreendaleGiske Ursin
Jun 26, 2003·JAMA : the Journal of the American Medical Association·Rowan T ChlebowskiUNKNOWN WHI Investigators
Aug 21, 2003·Lancet·Valerie Beral, UNKNOWN Million Women Study Collaborators
Aug 21, 2003·Lancet·Pierre-Yves ScarabinUNKNOWN EStrogen and THromboEmbolism Risk Study Group
Oct 2, 2003·JAMA : the Journal of the American Medical Association·Jane A CauleyUNKNOWN Women's Health Initiative Investigators
Mar 5, 2004·The New England Journal of Medicine·Rowan T ChlebowskiUNKNOWN Women's Health Initiative Investigators

❮ Previous
Next ❯

Citations

Apr 14, 2012·Journal of Biomedicine & Biotechnology·Massimiliano CazzanigaAliana Guerrieri-Gonzaga
Mar 25, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Christy G WoolcottChristine M Friedenreich
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea DecensiBernardo Bonanni
Aug 2, 2012·Journal of Biomedicine & Biotechnology·Massimiliano Cazzaniga, Bernardo Bonanni
Dec 6, 2007·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Carlo CampagnoliClementina Peris
Dec 26, 2009·Critical Reviews in Oncology/hematology·Ilaria SognoAdriana Albini
Sep 5, 2007·The Breast : Official Journal of the European Society of Mastology·Davide SerranoAndrea Decensi
Jul 23, 2014·Menopause : the Journal of the North American Menopause Society·Sebastian MirkinBarry S Komm
Dec 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debora MacisAndrea Decensi
Dec 1, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea DeCensi, Alessandra Gennari
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea DecensiBernardo Bonanni
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carol J Fabian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.